n,n-dimethyltryptamine has been researched along with Drug Withdrawal Symptoms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chwalek, M; Grieder, TE; Maal-Bared, G; Ting-A-Kee, R; van der Kooy, D; Vargas-Perez, H | 1 |
| Baumann, P; Carpenter, WT; Fujimori, M; Himwich, HE; Hokanson, L; Narasimhachari, N; Pak, HS; Zocchi, AF | 1 |
2 other study(ies) available for n,n-dimethyltryptamine and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
A single administration of the hallucinogen, 4-acetoxy-dimethyltryptamine, prevents the shift to a drug-dependent state and the expression of withdrawal aversions in rodents.
Topics: Animals; Brain-Derived Neurotrophic Factor; Hallucinogens; Heroin Dependence; Male; Mice; Mice, Inbred C57BL; N,N-Dimethyltryptamine; Rats; Rats, Wistar; Serotonin 5-HT2 Receptor Antagonists; Substance Withdrawal Syndrome; Tryptamines; Ventral Tegmental Area | 2017 |
Gas chromatographic-mass spectrometric identification of urinary bufotenin and dimethyltryptamine in drug-free chronic schizophrenic patients.
Topics: Chromatography, Gas; Chromatography, Thin Layer; Chronic Disease; Diet; Hallucinogens; Humans; Male; Mass Spectrometry; Methods; N,N-Dimethyltryptamine; Placebos; Schizophrenia; Spectrometry, Fluorescence; Substance Withdrawal Syndrome; Tryptamines | 1974 |